J Korean Med Sci.  2011 Aug;26(8):1014-1022. 10.3346/jkms.2011.26.8.1014.

Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy

• Yu JI
• Park HC
• Lim DH
• Park W
• Yoo BC
• Paik SW
• Koh KC
• Lee JH

• KMID: 1777839
• DOI: http://doi.org/10.3346/jkms.2011.26.8.1014

Abstract

We performed a retrospective review of 281 hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) treated with radiation therapy (RT) between 1998 and 2008 to develop a prognostic model for those patients. Of the 281 patients, PVTT and intrahepatic main masses completely disappeared in 10 patients (3.6%), and shown a partial response in 141 patients (50.2%). The median survival was 11.6 months. Patients who had more than PR have shown significantly longer survival than the others (22.0 months vs 5.0 months, P < 0.001). On the multivariate analysis, pre-treatment poor prognosticators for overall survival were ECOG performance status, Child-Pugh class, multiple tumors, main PVTT, complete portal vein occlusion, lymph node metastasis, and primary tumor size. Prognostic index of RT for PVTT of HCC (PITH) scores were defined as the number of pre-treatment poor prognostic factors. PITH scores correlated well with overall survival. In the analysis of 1 and 2 yr overall survival rate, patients who had PITH scores of 3 or greater showed a significantly lower rate of overall survival than the others (33.0%, 17.3% vs 70.1%, 40.8%, respectively, P < 0.001). The PITH scoring model, proposed in the current study in HCC patients with PVTT, reliably predict overall survival.

Keyword

Carcinoma, Hepatocellular; Portal Vein Tumor Thrombosis; Radiotherapy; Prognostic Index

MeSH Terms

Adult
Aged
Aged, 80 and over
Carcinoma, Hepatocellular/complications/mortality/*radiotherapy
Humans
Kaplan-Meier Estimate
Liver Neoplasms/complications/mortality/*radiotherapy
Male
Middle Aged
Neoplasm Staging
*Portal Vein
Prognosis
Retrospective Studies
Severity of Illness Index
Tomography, X-Ray Computed
Venous Thrombosis/complications/mortality/*radiotherapy

Figure

• 

  Fig. 1 Overall survival and portal vein tumor thrombosis progression free survival of all patients: Kaplan-Meier curves for overall survival (A) and portal vein tumor thrombosis (PVTT) progression free survival (B) rate of all patients with hepatocellular carcinoma (HCC) and PVTT treated with radiation therapy (RT).

• 

  Fig. 2 Overall survival according to the RT response: Kaplan-Meier curves for overall survival rate according to the RT response.

• 

  Fig. 3 Overall survival according to PITH scoring (A, all groups; B, 4 groups; C, 2 groups): Kaplan-Meier curves for overall survival rate according to PITH scoring. PITH score was calculated by the number of prognostic factors; ECOG performance status (≥ 2), Child-Pugh class (B or C), multiple tumor (more than 2), main PVTT, complete portal vein occlusion, lymph node metastasis, and primary tumor size (≥ 10 cm). PITH scores correlated well with OS (A). Patients were divided into four groups (B) and two groups (C) for statistical analyses.

Reference

1. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011. 15:223–243.

2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008. 7:237–257.

3. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000. 31:840–845.

4. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2008. 23:467–473.

5. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999. 29:62–67.

6. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, Nam HR, Ahn YC, Huh SJ. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005. 61:1143–1150.

7. Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer. 2005. 103:2419–2426.

8. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009. 185:782–788.

9. Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol. 2004. 10:88–98.

10. Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, Sagrini E, Imbriaco G, Pinna AD, Bolondi L. Bologna Liver Transplant Group. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl. 2010. 16:658–667.

11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009. 10:25–34.

12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008. 359:378–390.

13. Liang SX, Zhu XD, Lu HJ, Pan CY, Li FX, Huang QF, Wang AY, Chen L, Fu XL, Jiang GL. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer. 2005. 103:2181–2188.

14. Seong J, Park HC, Han KH, Chon CY, Chu SS, Kim GE, Suh CO. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res. 2003. 27:30–35.

15. Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Ye SL, Yeoh EM, Yeo W. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver Int. 2010. 30:1427–1438.

16. Kim H, Lim DH, Paik SW, Yoo BC, Koh KG, Lee JH, Choi MS, Park W, Park HC, Huh SJ, Choi DH, Ahn YC. Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma. Radiother Oncol. 2009. 93:302–306.

17. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002. 54:150–155.

18. Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009. 73:1155–1163.

19. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2003. 57:113–119.

20. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol. 2009. 15:391–423.

21. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J. 2009. 50:601–612.

22. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009. 29:502–510.

23. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999. 19:329–338.

24. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998. 28:751–755.

25. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985. 56:918–928.

26. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology. 2008. 75:Suppl 1. 83–90.

27. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002. 94:1760–1769.